Announces Appointment of Dr. Hugh Brady
to Board of Directors
Dublin, Ireland, April 30th, 2014 - ICON plc, (NASDAQ: ICLR), a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries, today announced the appointment of Dr. Hugh Brady as a non-executive director.
Dr. Brady is President Emeritus of University College Dublin (UCD), one of Europe's leading research-intensive universities, where he served as President from 2004 until the end of 2013.
tenure Dr. Brady
oversaw a significant expansion of UCD's
science, engineering and biomedical research capacity, including the development of the Conway Institute for Biomedical Research, UCD Clinical Research Centre and the Dublin Academic Medical Centre
In addition, he
led a major growth in UCD's international footprint, including the establishment of the Beijing-Dublin International College
and the UCD Shenzhen Health Sciences Institute
A nephrologist by training, Dr. Brady was Professor of Medicine and Therapeutics at UCD before being appointed the university's President.
He returned to Ireland having built a successful career as a physician and biomedical research scientist in the US, where he spent nine years at Harvard University, including a period as Associate Professor of Medicine.
In parallel with his academic career at Harvard, he served as Director of the Renal Division of the Brockton/West Roxbury VA Medical Center and Consultant Physician at the Brigham and Women's Hospital, Boston.
has an international reputation in the pathogenesis of diabetic kidney disease and renal inflammation.
Dr. Brady has held many national and international leadership roles, including Chairman of the Irish Health Research Board and Chairman of the Universitas 21 Network of global research universities.
He is also a non-executive director of Kerry Group plc.
"I am very pleased that Dr Brady has joined the board" commented Mr. Thomas Lynch, Chairman.